 Huntington Disease
"Huntington Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Descriptor ID |
D006816
|
| MeSH Number(s) |
C10.228.140.079.545 C10.228.140.380.278 C10.228.662.262.249.750 C10.574.500.497 C16.320.400.430 F03.087.250.400 F03.087.400.390
|
| Concept/Terms |
Huntington Disease- Huntington Disease
- Huntington Chorea
- Chorea, Huntington
- Huntington's Disease
- Huntington Chronic Progressive Hereditary Chorea
- Progressive Chorea, Hereditary, Chronic (Huntington)
- Chronic Progressive Hereditary Chorea (Huntington)
- Chorea, Chronic Progressive Hereditary (Huntington)
- Huntington's Chorea
- Chorea, Huntington's
- Progressive Chorea, Chronic Hereditary (Huntington)
Juvenile Huntington Disease- Juvenile Huntington Disease
- Juvenile-Onset Huntington Disease
- Juvenile Onset Huntington Disease
- Huntington Disease, Juvenile-Onset
- Huntington Disease, Juvenile Onset
- Huntington Disease, Juvenile
|
Below are MeSH descriptors whose meaning is more general than "Huntington Disease".
Below are MeSH descriptors whose meaning is more specific than "Huntington Disease".
This graph shows the total number of publications written about "Huntington Disease" by people in UAMS Profiles by year, and whether "Huntington Disease" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 2 | 0 | 2 | | 2022 | 7 | 0 | 7 | | 2021 | 2 | 0 | 2 | | 2020 | 1 | 0 | 1 | | 2019 | 2 | 0 | 2 | | 2016 | 1 | 0 | 1 | | 2011 | 1 | 0 | 1 | | 2005 | 0 | 1 | 1 | | 2003 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Huntington Disease" by people in Profiles over the past ten years.
-
Furr Stimming E, Claassen DO, Kayson E, Goldstein J, Mehanna R, Zhang H, Liang GS, Haubenberger D. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2023 06; 22(6):494-504.
-
Mahdi WA, AlGhamdi SA, Alghamdi AM, Imam SS, Alshehri S, Almaniea MA, Hajjar BM, Al-Abbasi FA, Sayyed N, Kazmi I. Neuroprotectant Effects of Hibiscetin in 3-Nitropropionic Acid-Induced Huntington's Disease via Subsiding Oxidative Stress and Modulating Monoamine Neurotransmitters in Rats Brain. Molecules. 2023 Feb 01; 28(3).
-
Schultz JL, Langbehn DR, Al-Kaylani HM, van der Plas E, Koscik TR, Epping EA, Espe-Pfeifer PB, Martin EP, Moser DJ, Magnotta VA, Nopoulos PC. Longitudinal Clinical and Biological Characteristics in Juvenile-Onset Huntington's Disease. Mov Disord. 2023 01; 38(1):113-122.
-
Frank S, Testa C, Edmondson MC, Goldstein J, Kayson E, Leavitt BR, Oakes D, O'Neill C, Vaughan C, Whaley J, Gross N, Gordon MF, Savola JM. The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study. CNS Drugs. 2022 11; 36(11):1207-1216.
-
Schultz JL, Epping EA, van der Plas E, Magnotta VA, Nopoulos PC. Striatal Development in Early-Onset Huntington's Disease. Mov Disord. 2022 12; 37(12):2459-2460.
-
Reasoner EE, van der Plas E, Al-Kaylani HM, Langbehn DR, Conrad AL, Schultz JL, Epping EA, Magnotta VA, Nopoulos PC. Behavioral features in child and adolescent huntingtin gene-mutation carriers. Brain Behav. 2022 07; 12(7):e2630.
-
Byrne LM, Schultz JL, Rodrigues FB, van der Plas E, Langbehn D, Nopoulos PC, Wild EJ. Neurofilament Light Protein as a Potential Blood Biomarker for Huntington's Disease in Children. Mov Disord. 2022 07; 37(7):1526-1531.
-
Alshehri S, Al-Abbasi FA, Ghoneim MM, Imam SS, Afzal M, Alharbi KS, Nadeem MS, Sayyed N, Kazmi I. Anti-Huntington's Effect of Butin in 3-Nitropropionic Acid-Treated Rats: Possible Mechanism of Action. Neurotox Res. 2022 Feb; 40(1):66-77.
-
Reasoner EE, van der Plas E, Langbehn DR, Conrad AL, Koscik TR, Epping EA, Magnotta VA, Nopoulos PC. Cortical Features in Child and Adolescent Carriers of Mutant Huntingtin (mHTT). J Huntingtons Dis. 2022; 11(2):173-178.
-
Nedosekin DA, Chen T, Ayyadevara S, Zharov VP, Shmookler Reis RJ. Label-free photothermal disruption of cytotoxic aggregates rescues pathology in a C. elegans model of Huntington's disease. Sci Rep. 2021 10 05; 11(1):19732.
-
Thota SM, Chan KL, Pradhan SS, Nagabushana B, Priyanka GB, Sunil HV, Kanneganti V, Vasoya P, Vinnakote KM, Viswamitra S, Thambisetty M, Kumar D, Tiwari V, Joshy EV, Sivaramakrishnan V. Multimodal Imaging and Visual Evoked Potentials Reveal Key Structural and Functional Features That Distinguish Symptomatic From Presymptomatic Huntington's Disease Brain. Neurol India. 2021 Sep-Oct; 69(5):1247-1258.
-
van der Plas E, Schultz JL, Nopoulos PC. The Neurodevelopmental Hypothesis of Huntington's Disease. J Huntingtons Dis. 2020; 9(3):217-229.
-
van der Plas E, Langbehn DR, Conrad AL, Koscik TR, Tereshchenko A, Epping EA, Magnotta VA, Nopoulos PC. Abnormal brain development in child and adolescent carriers of mutant huntingtin. Neurology. 2019 Sep 03; 93(10):e1021-e1030.
-
van der Plas E, Schubert R, Reilmann R, Nopoulos PC. A Feasibility Study of Quantitative Motor Assessments in Children Using the Q-Motor Suite. J Huntingtons Dis. 2019; 8(3):333-338.
-
Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, O'Neill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, Roman OC, Sung V, Smith J, Janicki S, Clouse R, Saint-Hilaire M, Hohler A, Turpin D, James RC, Rodriguez R, Rizer K, Anderson KE, Heller H, Carlson A, Criswell S, Racette BA, Revilla FJ, Nucifora F, Margolis RL, Ong M, Mendis T, Mendis N, Singer C, Quesada M, Paulsen JS, Brashers-Krug T, Miller A, Kerr J, Dubinsky RM, Gray C, Factor SA, Sperin E, Molho E, Eglow M, Evans S, Kumar R, Reeves C, Samii A, Chouinard S, Beland M, Scott BL, Hickey PT, Esmail S, Fung WL, Gibbons C, Qi L, Colcher A, Hackmyer C, McGarry A, Klos K, Gudesblatt M, Fafard L, Graffitti L, Schneider DP, Dhall R, Wojcieszek JM, LaFaver K, Duker A, Neefus E, Wilson-Perez H, Shprecher D, Wall P, Blindauer KA, Wheeler L, Boyd JT, Houston E, Farbman ES, Agarwal P, Eberly SW, Watts A, Tariot PN, Feigin A, Evans S, Beck C, Orme C, Edicola J, Christopher E. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. JAMA. 2016 Jul 05; 316(1):40-50.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|